動物用API製造の世界市場レポート 2025年

動物用API製造の市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は8.6％で、111億9,000万米ドルに成長します。予測期間の成長は、個別化獣医医療の進歩、世界化と市場拡大、規制遵守への注力、動物福祉の重要性の高まり、ドラッグデリバリーシステムの進歩、栄養補助食品需要の高まりに起因すると考えられます。予測期間の世界の動向には、製造プロセスの技術的進歩、API製造のアウトソーシングの増加、バイオテクノロジーベースのAPIへのシフト、製造のデジタル化と自動化、動物用API市場の世界化などが含まれます。

ペットの飼い主の増加は、今後の動物用API製造市場の成長を促進すると予測されています。ペットの飼い主とは、ペットの動物を所有または飼育し、その動物に必要不可欠な健康サービスを提供する個人であり、それによって動物用医薬品の需要が増加します。例えば、オーストラリアに本部を置く非政府組織であるAnimal Medicines Australiaは、2022年にペット所有者数が2021年の39%から28,730.8人に達し、ペット所有の著しい成長を報告しています。これはペットの飼育と世話への投資の強い増加傾向を反映しており、24％の増加を示しています。ペット飼育の急増は、オーストラリアの家庭におけるペットの人気の高まりを浮き彫りにしています。その結果、ペットの所有者数の増加が動物用API製造市場に拍車をかけています。

人獣共通感染症の増加は、動物用API製造市場の成長を促進すると予想されます。人獣共通感染症（ズーノーシス）とは、動物と人間の間で自然に感染する感染症のことです。動物用医薬品原薬は、動物からヒトへの人獣共通感染症のトランスミッションを予防するワクチンの開発に利用されます。さらに、動物用原薬の使用は、人獣共通感染症の治療において重要な懸念事項である抗生物質耐性を緩和するのに役立ちます。例えば、米国を拠点とする独立系超党派組織でシンクタンクの外交問題評議会（CFR）は2023年2月、新たに発見された感染症や新興感染症（EID）の最大75％、認知されている感染症の60％が人獣共通感染症を起源としていると報告しました。人獣共通感染症は、世界全体で毎年270万人の人間の死亡と25億件の疾病の原因となっています。したがって、人獣共通感染症の蔓延が動物用API製造市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の動物用API製造PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の動物用API製造市場：成長率分析
• 世界の動物用API製造市場の実績：規模と成長, 2019-2024
• 世界の動物用API製造市場の予測：規模と成長, 2024-2029, 2034F
• 世界の動物用API製造総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の動物用API製造市場：サービスタイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 社内
• 契約アウトソーシング
• 世界の動物用API製造市場：合成タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学ベースのAPI
• 生物学的API
• ハイポテンシャルAPI
• 世界の動物用API製造市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 駆虫薬
• 抗感染薬
• ワクチン
• NSAIDs
• 世界の動物用API製造市場：駆虫薬のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• エンデクトサイド
• 駆虫薬
• 抗原虫
• 世界の動物用API製造市場：抗感染薬のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗生物質
• 抗真菌薬
• 抗ウイルス薬
• 世界の動物用API製造市場：ワクチンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 不活化ワクチン
• 生弱毒化ワクチン
• 組み換えワクチン
• 世界の動物用API製造市場：NSAIDsのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非選択的NSAID
• COX-2阻害剤

第7章 地域別・国別分析

• 世界の動物用API製造市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の動物用API製造市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 動物用API製造市場：競合情勢
• 動物用API製造市場：企業プロファイル
  • Alivira Animal Health Limited Overview, Products and Services, Strategy and Financial Analysis
  • Excel Industries Limited Overview, Products and Services, Strategy and Financial Analysis
  • Ofichem Group B.V. Overview, Products and Services, Strategy and Financial Analysis
  • Jiangsu Lingyun Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • SUANFARMA S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• NGL Fine-Chem Limited
• FIS-Fabbrica Italiana Sintetici S.p.A.
• Lupin Limited
• Aurobindo Pharma Limited
• Saneca Pharmaceuticals AS
• Neuland Laboratories Limited
• Divi's Laboratories Limited
• Zoetis Inc.
• Grupo Indukern S.L.
• Sequent Scientific Limited
• Chempro Pharma Private Limited
• AMGIS Lifescience Ltd.
• Huvepharma AD
• Vetpharma Animal Health S.L.
• Qilu Pharma Spain S.A.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 動物用API製造市場2029：新たな機会を提供する国
• 動物用API製造市場2029：新たな機会を提供するセグメント
• 動物用API製造市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Veterinary Active Pharmaceutical Ingredients (APIs) manufacturing involves the production of chemical compounds that are biologically active and utilized in the formulation of veterinary medicines. These APIs play a crucial role in treating diseases and maintaining health in animals, including both livestock and pets. The manufacturing process is designed to ensure the quality, safety, and efficacy of the medications that enhance animal welfare and health outcomes.

The primary products within veterinary active pharmaceutical ingredients manufacturing encompass anti-infectives, vaccines, and NSAIDs. Active Pharmaceutical Ingredients (APIs) are the core elements of pharmaceutical medications that exert specific effects on the body, aiding in the treatment of diseases. Service types associated with this field include in-house production and contract outsourcing. Additionally, synthetic types of APIs comprise chemical-based APIs, biological APIs, and highly potent APIs. These categories delineate the diverse methodologies involved in producing these vital components for veterinary pharmaceuticals.

The veterinary active pharmaceutical ingredients manufacturing market research report is one of a series of new reports from The Business Research Company that provides veterinary active pharmaceutical ingredients manufacturing market statistics, including veterinary active pharmaceutical ingredients manufacturing industry global market size, regional shares, competitors with veterinary active pharmaceutical ingredients manufacturing market share, detailed veterinary active pharmaceutical ingredients manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary active pharmaceutical ingredients manufacturing industry. This veterinary active pharmaceutical ingredient manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The veterinary active pharmaceutical ingredients manufacturing market size has grown strongly in recent years. It will grow from $7.46 billion in 2024 to $8.05 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to rising pet ownership, stringent regulatory standards, increased focus on animal nutrition, research and development investments, global economic growth.

The veterinary active pharmaceutical ingredients manufacturing market size is expected to see strong growth in the next few years. It will grow to $11.19 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to advancements in personalized veterinary medicine, globalization and market expansion, focus on regulatory compliance, growing importance of animal welfare, advancements in drug delivery systems, rising demand for nutraceuticals. Major trends in the forecast period include technological advancements in manufacturing processes, increasing outsourcing of API manufacturing, shift toward biotechnology-based APIs, digitalization and automation in manufacturing, globalization of the veterinary API market.

The rising number of pet owners is anticipated to drive the growth of the veterinary active pharmaceutical ingredients manufacturing market in the future. Pet owners are individuals who own or adopt pet animals and provide essential health services for them, thereby increasing the demand for veterinary drugs. For example, in 2022, Animal Medicines Australia, a non-governmental organization based in Australia, reported significant growth in pet ownership, with the number of pet owners reaching 28,730.8 in 2022, up from 39% in 2021. This marks a 24% increase, reflecting a strong upward trend in pet adoption and investment in care. The surge in pet ownership highlights the increasing popularity of pets in Australian households. Consequently, the growing number of pet owners is fueling the veterinary active pharmaceutical ingredients manufacturing market.

The increasing prevalence of zoonotic diseases is expected to boost the growth of the veterinary active pharmaceutical ingredients manufacturing market moving forward. A zoonotic disease, or zoonosis, is an infectious disease that can be naturally transmitted between animals and humans. Veterinary APIs are utilized in the development of vaccines that prevent the transmission of zoonotic diseases from animals to humans. Additionally, the use of veterinary APIs can help mitigate antibiotic resistance, which is a significant concern in treating zoonotic diseases. For instance, in February 2023, the Council on Foreign Relations (CFR), a U.S.-based independent, nonpartisan organization and think tank, reported that up to 75% of newly discovered or emerging infectious diseases (EIDs) and 60% of recognized infectious diseases have zoonotic origins. Zoonoses are responsible for 2.7 million human deaths and 2.5 billion cases of disease globally each year. Therefore, the increasing prevalence of zoonotic diseases is driving the growth of the veterinary active pharmaceutical ingredients manufacturing market.

Product innovation is a significant trend gaining traction in the veterinary active pharmaceutical ingredient manufacturing market. Key players in the industry are concentrating on developing innovative products to maintain their market positions. For example, in January 2022, Zoetis Inc., a U.S.-based company specializing in drugs for pets and livestock, announced the U.S. FDA approval of Solensia (frunevetmab injection) for managing osteoarthritis (OA) pain in cats. Solensia is the first injectable monoclonal antibody treatment for feline OA pain approved in the United States, functioning by targeting and neutralizing nerve growth factor (NGF), a primary contributor to pain in osteoarthritis.

Leading companies in the veterinary active pharmaceutical ingredient manufacturing market are focused on establishing manufacturing plants for APIs to gain a competitive advantage. These facilities produce active pharmaceutical ingredients used in veterinary drug formulations. For instance, in October 2023, Stallen South Asia Private Limited, an India-based animal health company, launched and commenced operations at a new veterinary API facility for Halquinol, a non-antibiotic growth promoter from the hydroxyquinoline group. This product is a combination of 5-chloro-8-hydroxyquinoline, 5,7-dichloro-8-hydroxyquinoline, and 7-chloro-8-hydroxyquinoline. The facility produces Halquinol 98%, manufactured in accordance with British Pharmacopeia 1980 (BP 80) guidelines. Alongside the more common 60% and 12% formulations, Stallen can also offer 98% as a chemical API used in veterinary formulations and feed additives. Stallen aims to reduce the dependence on products sourced from China for the animal health industry by gradually introducing a diverse range of APIs from this facility.

In June 2022, Orion Corporation, a Finland-based company in the human and veterinary pharmaceutical industry, acquired Inovet (V.M.D. nv/sa) for $128.33 million (130 million euros). This acquisition will allow Orion's Veterinary Medicines division to expand its product portfolio and establish a presence in the production animal market, as well as increase its geographical reach in Western Europe and the export market. Inovet (V.M.D. nv/sa) is a Belgium-based manufacturer of veterinary active pharmaceutical ingredients.

Major companies operating in the veterinary active pharmaceutical ingredients manufacturing market are Alivira Animal Health Limited, Excel Industries Limited, Ofichem Group B.V., Jiangsu Lingyun Pharmaceutical Co. Ltd., SUANFARMA S.A., NGL Fine-Chem Limited, FIS - Fabbrica Italiana Sintetici S.p.A., Lupin Limited, Aurobindo Pharma Limited, Saneca Pharmaceuticals AS, Neuland Laboratories Limited, Divi's Laboratories Limited, Zoetis Inc., Grupo Indukern S.L., Sequent Scientific Limited, Chempro Pharma Private Limited, AMGIS Lifescience Ltd., Huvepharma AD, Vetpharma Animal Health S.L., Qilu Pharma Spain S.A., INDUKERN Chemie AG, Chemopharma S.A., Norbrook Laboratories Limited, Ceva Sante Animale S.A., Vetoquinol S.A., Virbac S.A.

North America was the largest region in the veterinary active pharmaceutical ingredients manufacturing market in 2024. The regions covered in the veterinary active pharmaceutical ingredients manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the veterinary active pharmaceutical ingredients manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The veterinary active pharmaceutical ingredients manufacturing market consists of revenues earned by entities by biologics and bulk drugs that are used to create components in medications which are responsible for the positive veterinary health impacts. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Veterinary Active Pharmaceutical Ingredients Manufacturing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on veterinary active pharmaceutical ingredients manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for veterinary active pharmaceutical ingredients manufacturing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The veterinary active pharmaceutical ingredients manufacturing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Antiparasitic; Anti-Infectives; Vaccines; NSAIDs
• 2) By Service Type: In House; Contract Outsourcing
• 3) By Synthesis Type: Chemical Based API; Biological API; Highly Potent API
• Subsegments:
• 1) By Antiparasitic: Endectocides; Anthelmintics; Antiprotozoals
• 2) By Anti-Infectives: Antibiotics; Antifungals; Antivirals
• 3) By Vaccines: Inactivated Vaccines; Live Attenuated Vaccines; Recombinant Vaccines
• 4) By NSAIDs (Non-Steroidal Anti-Inflammatory Drugs): Non-Selective NSAIDs; COX-2 Inhibitors
• Companies Mentioned: Alivira Animal Health Limited; Excel Industries Limited; Ofichem Group B.V.; Jiangsu Lingyun Pharmaceutical Co. Ltd.; SUANFARMA S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Characteristics

3. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Trends And Strategies

4. Veterinary Active Pharmaceutical Ingredients Manufacturing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Growth Analysis And Strategic Analysis Framework

• 5.1. Global Veterinary Active Pharmaceutical Ingredients Manufacturing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market Growth Rate Analysis
• 5.4. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Total Addressable Market (TAM)

6. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Segmentation

• 6.1. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• In House
• Contract Outsourcing
• 6.2. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemical Based API
• Biological API
• Highly Potent API
• 6.3. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiparasitic
• Anti-Infectives
• Vaccines
• NSAIDs
• 6.4. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Sub-Segmentation Of Antiparasitic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Endectocides
• Anthelmintics
• Antiprotozoals
• 6.5. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Sub-Segmentation Of Anti-Infectives, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antibiotics
• Antifungals
• Antivirals
• 6.6. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inactivated Vaccines
• Live Attenuated Vaccines
• Recombinant Vaccines
• 6.7. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Sub-Segmentation Of NSAIDs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Selective NSAIDs
• COX-2 Inhibitors

7. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Regional And Country Analysis

• 7.1. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Veterinary Active Pharmaceutical Ingredients Manufacturing Market

• 8.1. Asia-Pacific Veterinary Active Pharmaceutical Ingredients Manufacturing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Veterinary Active Pharmaceutical Ingredients Manufacturing Market

• 9.1. China Veterinary Active Pharmaceutical Ingredients Manufacturing Market Overview
• 9.2. China Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Veterinary Active Pharmaceutical Ingredients Manufacturing Market

• 10.1. India Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Veterinary Active Pharmaceutical Ingredients Manufacturing Market

• 11.1. Japan Veterinary Active Pharmaceutical Ingredients Manufacturing Market Overview
• 11.2. Japan Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Veterinary Active Pharmaceutical Ingredients Manufacturing Market

• 12.1. Australia Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Veterinary Active Pharmaceutical Ingredients Manufacturing Market

• 13.1. Indonesia Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Veterinary Active Pharmaceutical Ingredients Manufacturing Market

• 14.1. South Korea Veterinary Active Pharmaceutical Ingredients Manufacturing Market Overview
• 14.2. South Korea Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market

• 15.1. Western Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market Overview
• 15.2. Western Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Veterinary Active Pharmaceutical Ingredients Manufacturing Market

• 16.1. UK Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Veterinary Active Pharmaceutical Ingredients Manufacturing Market

• 17.1. Germany Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Veterinary Active Pharmaceutical Ingredients Manufacturing Market

• 18.1. France Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Veterinary Active Pharmaceutical Ingredients Manufacturing Market

• 19.1. Italy Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Veterinary Active Pharmaceutical Ingredients Manufacturing Market

• 20.1. Spain Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market

• 21.1. Eastern Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market Overview
• 21.2. Eastern Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Veterinary Active Pharmaceutical Ingredients Manufacturing Market

• 22.1. Russia Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Veterinary Active Pharmaceutical Ingredients Manufacturing Market

• 23.1. North America Veterinary Active Pharmaceutical Ingredients Manufacturing Market Overview
• 23.2. North America Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Veterinary Active Pharmaceutical Ingredients Manufacturing Market

• 24.1. USA Veterinary Active Pharmaceutical Ingredients Manufacturing Market Overview
• 24.2. USA Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Veterinary Active Pharmaceutical Ingredients Manufacturing Market

• 25.1. Canada Veterinary Active Pharmaceutical Ingredients Manufacturing Market Overview
• 25.2. Canada Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Veterinary Active Pharmaceutical Ingredients Manufacturing Market

• 26.1. South America Veterinary Active Pharmaceutical Ingredients Manufacturing Market Overview
• 26.2. South America Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Veterinary Active Pharmaceutical Ingredients Manufacturing Market

• 27.1. Brazil Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Veterinary Active Pharmaceutical Ingredients Manufacturing Market

• 28.1. Middle East Veterinary Active Pharmaceutical Ingredients Manufacturing Market Overview
• 28.2. Middle East Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Veterinary Active Pharmaceutical Ingredients Manufacturing Market

• 29.1. Africa Veterinary Active Pharmaceutical Ingredients Manufacturing Market Overview
• 29.2. Africa Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Competitive Landscape And Company Profiles

• 30.1. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Competitive Landscape
• 30.2. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Company Profiles
  • 30.2.1. Alivira Animal Health Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Excel Industries Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Ofichem Group B.V. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Jiangsu Lingyun Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. SUANFARMA S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Other Major And Innovative Companies

• 31.1. NGL Fine-Chem Limited
• 31.2. FIS - Fabbrica Italiana Sintetici S.p.A.
• 31.3. Lupin Limited
• 31.4. Aurobindo Pharma Limited
• 31.5. Saneca Pharmaceuticals AS
• 31.6. Neuland Laboratories Limited
• 31.7. Divi's Laboratories Limited
• 31.8. Zoetis Inc.
• 31.9. Grupo Indukern S.L.
• 31.10. Sequent Scientific Limited
• 31.11. Chempro Pharma Private Limited
• 31.12. AMGIS Lifescience Ltd.
• 31.13. Huvepharma AD
• 31.14. Vetpharma Animal Health S.L.
• 31.15. Qilu Pharma Spain S.A.

32. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Veterinary Active Pharmaceutical Ingredients Manufacturing Market

34. Recent Developments In The Veterinary Active Pharmaceutical Ingredients Manufacturing Market

35. Veterinary Active Pharmaceutical Ingredients Manufacturing Market High Potential Countries, Segments and Strategies

• 35.1 Veterinary Active Pharmaceutical Ingredients Manufacturing Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Veterinary Active Pharmaceutical Ingredients Manufacturing Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Veterinary Active Pharmaceutical Ingredients Manufacturing Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer